Journal of Otology 13 (2018) 54–58

Contents lists available at ScienceDirect

Journal of Otology

journal homepage: www.journals.elsevier.com/journal-of-otology/

Pharmacokinetics of sodium thiosulfate in Guinea pig perilymph following middle ear application

Ronald J. Schroeder II *, Jason Audlin, Juntao Luo, Brian D. Nicholas

SUNY Upstate Medical University, USA

ARTICLE INFO

Article history:
Received 12 October 2017
Received in revised form
29 November 2017
Accepted 5 December 2017

Keywords:
Sodium thiosulfate
Pharmacokinetics
Perilymph
Cisplatin
Ototoxicity

ABSTRACT

Hypothesis: To determine the pharmacokinetics of sodium thiosulfate in the inner ear perilymph following middle ear application in Guinea pigs.
Background: Cisplatin chemotherapy is often associated with a dose-dependent high frequency sensorineural hearing loss. Sodium thiosulfate has been shown to reduce cisplatin-induced ototoxicity when given intravenously, but this may limit the tumoricidal effects of the chemotherapy. Recent animal studies looking at middle ear application of sodium thiosulfate have shown prevention of outer hair cell and hearing loss, but the perilymph pharmacokinetics have not yet been established.
Methods: Twenty Guinea pig ears were split into two groups and administered sodium thiosulfate to the middle ear at either a concentration of 250 mg/mL or 50 mg/mL for 30 min. Perilymph samples were then obtained serially through the round window over 6 h. Sodium thiosulfate concentrations were obtained using high-pressure liquid chromatography.
Results: The 250 mg/mL group had a maximum perilymph concentration of 7.27 mg/mL (±0.83) that decreased to 0.94 mg/mL (±0.03) over 6 h. The 50 mg/mL group had an initial concentration of 1.63 mg/mL (±0.17) and was undetectable after 1 h. The half-life of sodium thiosulfate within perilymph was 0.74 h.
Conclusions: and Relevance: The results of this study show that sodium thiosulfate is capable of diffusing through round window and into the inner ear perilymph. Peak levels decline over several hours after exposure. This has a potential application as a localized therapy in the prevention of cisplatin induced ototoxicity.

1. Introduction

Cisplatin is a commonly used chemotherapy agent in the treatment of a number of malignant tumors, both in children and adults. This type of chemotherapy is often associated with a dose-dependent bilateral high frequency sensorineural hearing loss. The incidence of cisplatin-induced hearing loss is reported to range from 22 to 77% (Schaefer et al., 1985; Bokemeyer et al., 1998; De jongh et al., 2003; Coradini et al., 2007; Knight et al., 2005; Kushner et al., 2006). The range reflects differences in cisplatin dose, as well as in measures of hearing outcomes. Additional risk factors for cisplatin-induced ototoxicity include children under five years in age, prior irradiation to the head and neck greater than 40 Gy, and prior hearing loss (Montaguti et al., 2002; Li et al., 2004; Hitchcock et al., 2009). Vestibular function can also be damaged by platinum-based toxicity (Moroso and Blair, 1983). The exact cellular mechanisms by which cisplatin causes cochlear hair cell loss is unclear. There is believed to be some degree of resultant oxidative stress with subsequent activation of apoptotic pathway in outer hair cells and the stria vascularis (Rybak, 2007). Other possible mechanisms include the activation of voltage-dependent big conductance potassium channels in type 1 spiral ligament fibrocytes of the lateral wall of the cochlea leading to disruption of the electrochemical gradient and the activation of apoptotic pathways (Liang et al., 2005). Finally, other postulated mechanisms include disruption to nuclear excision repair leading to aggregates of cisplatin-induced DNA adducts and inflammation from the induction of pro-inflammatory cytokines in the cochlea (Guthrie et al., 2008; So et al., 2008).

* Corresponding author. SUNY Upstate, Rm 241 Campus West Building (CWB), 750 E Adams St, Syracuse, NY 13210, USA.
E-mail address: schroedr@upstate.edu (R.J. Schroeder).
Peer review under responsibility of PLA General Hospital Department of Otolaryngology Head and Neck Surgery.

https://doi.org/10.1016/j.joto.2017.12.001

Sodium thiosulfate (STS) has shown potential as an otoprotective agent against platinum-based chemotherapy (Leitao and Blakley, 2003; Muldoon et al., 2000; Kaltenbach et al., 1997; Doolittle et al., 2001; Neuwelt et al., 1998; Zuur et al., 2007). STS is currently approved by the United States Food and Drug Administration (USFDA) as an antidote for cyanide and nitroprusside toxicity, and it is also used as an off-label treatment for cisplatin-related nephrotoxicity and calciphylaxis (Hall et al., 2007; Bourgeois and De Haes, 2016; Ossorio-Garcia et al., 2016; Yu et al., 2015; Gandara et al., 1990). Unlike several other potential otoprotectants, STS has been shown to act as both an antioxidant as well as a chelating agent (Gandara et al., 1990; Yerram et al., 2007; Marckmann et al., 2008). The chelating properties of the sulfur-thiol functional group are believed to be responsible for the otoprotective effects of STS by binding to and inactivating the platinum (Dedon and Borch, 1987). The thiol compound may also act to scavenge reactive oxygen species produced by the platinum, thus preventing the initiation of the apoptotic pathway (Dedon and Borch, 1987).

STS administered intravenously has been shown to prevent cisplatin-induced ototoxicity in animal models and *in vivo* (Leitao and Blakley, 2003; Muldoon et al., 2000; Kaltenbach et al., 1997; Doolittle et al., 2001; Neuwelt et al., 1998; Zuur et al., 2007). However, a major concern to this mode of delivery is that it may potentially reduce the tumoricidal activity of the platinum. Sodium thiosulfate is believed to bind to cisplatin, forming a complex that is then excreted by the kidneys. Such chelation could negatively impact the desired activity of the platinum. There are conflicting reports of reduced tumoricidal properties of STS in vitro (Harned et al., 2008; Yee et al., 2008). A recent *in vivo* study by Freyer et al. showed that infusion of intravenous 6% STS solution after cisplatin therapy was not found to have a statistically significant otoprotective effect in children with pediatric cancer. Additionally, patients with disseminated disease treated with STS were shown to have significantly lower 3-year overall survival (45%) compared to the control group (84%) (Freyer et al., 2017).

Local application of STS to the round window may represent an alternative mode of delivery that may allow for higher intracochlear concentrations while minimizing interference with the tumoricidal effects of cisplatin. There have been a few recent studies showing intratympanic STS as an effective means to prevent cisplatin-induced ototoxicity in animals (Wang et al., 2003; Berglin et al., 2011). However, the pharmacokinetics of STS via round window diffusion are not yet well understood. The purpose of this study is to establish pharmacokinetic parameters of STS in perilymph after intratympanic administration.

2. Materials and methods

2.1. Animal preparation and procedures

Ten retired breeder Hartley albino Guinea pigs of both sexes (Charles River, Kiβlegg, Germany) were used. Twenty ears were randomly separated into 2 groups based on STS (Hope Pharmaceuticals, Scottsdale, AZ) concentration: 50 mg/mL (5% solution) or 250 mg/mL (25% solution) (Fig. 1). These concentrations of STS were selected based on previous studies determining their safety. A 25% solution of STS has been used ototopically to prevent myringosclerosis in rat models and a 6% solution has also been used safely when administered ototopically in mice models (Park et al., 2010; Stocks et al., 2004). Each Guinea pig was placed under general anesthesia using inhaled 1–5% isoflurane for induction, then intubated endotracheally and placed on 2–4% isoflurane for maintenance anesthesia. The body temperature was maintained throughout the procedure with a temperature-controlled heating blanket. The head and neck was then shaved and 1% lidocaine with 1:100,000 epinephrine was injected in the postauricular soft tissue. A postauricular incision was then made extending to the neck and soft tissue was elevated off of bone. With the aid of an operating microscope, a cutting bur was then used on a high-speed drill to enter the bulla. The vertical portion of the facial nerve was drilled away in order to obtain adequate visualization of the round window. This procedure was then repeated on the contralateral ear.



Fig. 1. Flowchart of STS Randomization and perilymph sampling.

The protocol for STS middle ear application and perilymph sampling was adapted from similar studies looking at the pharmacokinetics of intratympanic steroids (Chandrasekhar et al., 2000; Plontke et al., 2008; Parnes et al., 1999; Wang et al., 2011; Hahn et al., 2012; Liu et al., 2006). With the head in a neutral position, STS was placed in the middle ear space for 30 min. An operating microscope was used to confirm the round window was covered with STS. After 30 min, we confirmed that the round window was still covered with STS ensuring none was lost via the Eustachian tube. The bulla was then suctioned and irrigated with normal saline. A 26-gauge needle attached to a 10 μL Hamilton syringe was then inserted into the round window, and 2 μL of perilymph was then aspirated from the scala tympani. Perilymph samples were obtained serially at 0, 30, 60, 180, and 360 min after the bulla was cleaned. In order to prevent perilymph lost between samples, the Guinea pig heads were kept in a neutral position for all samples. Additionally, no gush of perilymph was noted upon perforation of the round window. Samples were stored at −20° C and later analyzed by high pressure liquid chromatography (HPLC). Once all samples were obtained, intraperitoneal pentobarbital was injected for euthanasia. This study was performed in accordance with the Public Health Service Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animals, and the Animal Welfare Act. The Institutional Animal Care and Use Committee of SUNY Upstate Medical University approved the animal use protocol.

2.2. High pressure liquid chromatography (HPLC)

STS concentrations were quantitatively analyzed by HPLC using an LC-20AT with a SPD-M20A UV–Vis detector (Shimadzu, Kyoto, Japan) and a LiChrospher RP-select B LiChroCART 250-4 anion exchange column (EMD Millipore Corp, Darmstadt, Germany). All samples were prepared using a method similar to that described by Togawa et al. (1992). Two μL samples were diluted in 8 μL of sterile water. Ten μL of 5 mM monobromobimane in acetonitrile was then added and the mixture was allowed to sit for 60 min in the dark at room temperature. Ten μL of 0.05 M KCl-HCl buffer was then added. Ten μL of this mixture was then submitted to the HPLC system using

a mobile phase of 40% acetonitrile and 60% 36 mM succinate (pH 5.0) with a flow rate of 1.0 mL/min. Drug concentrations were calculated based on peak height. A linear standard curve was calibrated by testing serial dilutions of STS. Samples with an STS concentration less than 0.9 mg/mL were unable to be detected.

2.3. Data analysis

Statistical analysis was performed using SPSS Version 22 (IBM Corporation, Armonk NY, USA). Pharmacokinetic parameters and perilymph concentration–time curves were generated for each concentration of STS. The results are presented as means ± standard deviation (SD) whenever possible. Half-life and AUC were determined by generating a logarithmic line of best fit using the SPSS software.

3. Results

The pharmacokinetic parameters of each concentration of STS are summarized in Table 1. Peak concentrations of STS for the 250 mg/mL dose was found to be 7.27 mg/mL with a standard deviation of 0.83. The half life of STS 250 mg/mL within perilymph was 0.74 h (44.4 min). The half-life of STS 50 mg/mL was unable to be determined due to the inability to detect concentrations less than 0.9 mg/mL. Perilymph concentration–time curves are shown in Fig. 2.



Brackets note the standard deviation of each time point

Fig. 2. Perilymph Concentration–Time Curves After Intratympanic STS. *Brackets note the standard deviation of each time point.

4. Discussion

In light of the potential for systemic STS to reduce the tumoricidal effects of cisplatin, researchers have sought an alternate mode of delivery. Recent animal studies have examined the effect of sodium thiosulfate delivered locally to the middle ear space. Stocks et al., in 2004 demonstrated an otoprotective effect of 6% STS delivered to the middle ear space of Guinea pigs via both daily injections and continuous infusions (Stocks et al., 2004). Wang et al. (2003) showed complete prevention of the ototoxic effects of cisplatin in Guinea pigs treated with round window application of 10 mM (1.58 mg/mL) solution of STS via auditory brainstem response (ABR) studies. They also showed that both the compound action potential (CAP) and distortion product otoacoustic emissions (DPOAE) were preserved, and both outer hair cells (OHC) and inner hair cells (IHC) were preserved (Wang et al., 2003). Berglin et al. (2011) noted the prevention of IHC and OHC loss when a 0.1 M (15.8 mg/mL) concentration of STS was administered via a hyaluronic acid gel applied to the round window prior to cisplatin administration (Berglin et al., 2011). A study by Wimmer et al. (2004) showed higher DPOAEs in Guinea pigs treated with intratympanic 15 mg/mL STS compared to a control, but this was not found to be statistically significant (Wimmer et al., 2004).

This is the first study showing the perilymph pharmacokinetics of STS after intratympanic administration. Perilymph concentrations of STS following intratympanic administration in this study were about 200–1000 fold higher compared to perilymph concentrations following intravenous administration of a103 mg/kg STS solution found by Pierre et al. (2009). This shows that intratympanic administration of STS may be a more effective method of delivering STS to the perilymph than intravenously. STS has been shown to be safely used ototopically in the prevention of myringosclerosis in rats at a concentration of 250 mg/mL (Park et al., 2010). Stocks et al., in 2004 found STS to be safe with application to the middle ear space of Guinea pigs at a concentration of 6% (Stocks et al., 2004). A 5% STS solution has also been used to relieve iodine-induced mucosal irritation of the esophagus in the gastroenterology literature (Kondo et al., 2001). Our study used 5% and 25% STS solutions, and no evidence of a local inflammatory reaction or gross toxicity were noted throughout the study at either concentration. However, exposure times in this study were limited to 30 min, therefore the potential for more prolonged or repeated applications of STS to generate adverse local reactions remains unclear.

When considering this as a potential treatment modality, intratympanic STS should be administered around the time of peak cisplatin concentrations in perilymph. Multiple studies have looked at the pharmacokinetics of cisplatin in perilymph showing maximum concentrations occurring between 10 and 30 min after intravenous administration (Hellberg et al., 2009, 2013; Laurell et al., 1995; Saito et al., 1997). Based on these pharmacokinetic parameters, STS should be administered intratympanically immediately prior to administering IV cisplatin. This could be done either via an intratympanic injection or ototopical drops after myringotomy tube placement. Intratympanic injections would likely result in higher perilymph concentrations, however ototopical drops after myringotomy tube placement may be better tolerated and logistically easier to administer both at the time of cisplatin administration and in the ensuing days. With either route of application, losses from the Eustachian tube or through the myringotomy render some variability in the drug delivery to the perilymph.

There were some limitations encountered during this study. Samples were taken only from the base of the cochlea, so it cannot be reliably stated that STS was distributed evenly to the remaining portions of the cochlea or the vestibular system. Also, the use of a UV–Vis detector for HPLC is at least 100-fold less sensitive than a fluorescent detector. A fluorescent detector would have allowed us to detect smaller concentrations of STS and provided a more complete pharmacokinetic profile of STS 50 mg/mL, as well as assess serum samples for systemic absorption. Perilymph samples were also double that of similar pharmacokinetic studies (2 μL instead of 1 μL) to improve the likelihood of detection of STS, but

Table 1
Pharmacokinetic profile of STS in perilymph.

Parameters	STS 250 mg/mL	STS 50 mg/mL
C_{max} (mg/mL)[a]	7.27 ± 0.83	1.63 ± 0.17
T_{max} (hr)	0	0
AUC (mg hr/mL)	13.46	1.21
$T_{1/2}$ (hr)	0.74	–

[a] Range determined by standard deviation.

this also increases the dilution of samples with CSF as described by Salt et al. (2003). This effect will be more pronounced with successive sampling in the same animal, thus making our initial samples the most reliable. As a result, perilymph concentrations after the initial sampling may be underestimated and the calculated half-life of STS within the perilymph may actually be longer. Despite the dilution of subsequent samples, it is important to note that we were still able to identify STS within our samples up to 6 h after the initial sample.

5. Conclusion

This study shows that intratympanic STS has the potential to be a localized therapy in the prevention of cisplatin-induced ototoxicity. Local application of STS will allow for higher perilymphatic concentrations while limiting any interference with the tumoricidal effects of cisplatin.

Conflicts of interest and financial disclosures

Authors report no conflicts of interest or financial disclosures.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.joto.2017.12.001.

References

Berglin, C.E., Pierre, P.V., Bramer, T., et al., 2011. Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a Guinea pig model. Canc. Chemother. Pharmacol. 68 (6), 1547–1556.
Bokemeyer, C., Berger, C.C., Hartmann, J.T., et al., 1998. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Canc. 77 (8), 1355–1362.
Bourgeois, P., De Haes, P., 2016. Sodium thiosulfate as a treatment for calciphylaxis: a case series. J. Dermatol. Treat. 27 (6), 520–524.
Chandrasekhar, S.S., Rubinstein, R.Y., Kwartler, J.A., et al., 2000. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol. Head Neck Surg. 122 (4), 521–528.
Coradini, P.P., Cigana, L., Selistre, S.G., Rosito, L.S., Brunetto, A.L., 2007. Ototoxicity from cisplatin therapy in childhood cancer. J. Pediatr. Hematol. Oncol. 29, 355–360.
De jongh, F.E., Van veen, R.N., Veltman, S.J., et al., 2003. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Canc. 88 (8), 1199–1206.
Dedon, P.C., Borch, R.F., 1987. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem. Pharmacol. 36 (12), 1955–1964.
Doolittle, N.D., Muldoon, L.L., Brummett, R.E., et al., 2001. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin. Canc. Res. 7 (3), 493–500.
Freyer, D.R., Chen, L., Krailo, M.D., et al., 2017. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 18 (1), 63–74.
Gandara, D.R., Wiebe, V.J., Perez, E.A., Makuch, R.W., DeGregorio, M.W., 1990. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit. Rev. Oncol. Hematol. 10 (4), 353–365.
Guthrie, O.W., Li-korotky, H.S., Durrant, J.D., Balaban, C., 2008. Cisplatin induces cytoplasmic to nuclear translocation of nucleotide excision repair factors among spiral ganglion neurons. Hear. Res. 239 (1–2), 79–91.
Hahn, H., Salt, A.N., Biegner, T., et al., 2012. Dexamethasone levels and base-to-apex concentration gradients in the scala tympani perilymph after intracochlear delivery in the Guinea pig. Otol. Neurotol. 33 (4), 660–665.
Hall, A.H., Dart, R., Bogdan, G., 2007. Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Ann. Emerg. Med. 49 (6), 806–813.
Harned, T.M., Kalous, O., Neuwelt, A., et al., 2008. Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin. Canc. Res. 14 (2), 533–540.
Hellberg, V., Wallin, I., Eriksson, S., et al., 2009. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J. Natl. Cancer Inst. 101 (1), 37–47.
Hellberg, V., Wallin, I., Ehrsson, H., Laurell, G., 2013. Cochlear pharmacokinetics of cisplatin: an in vivo study in the Guinea pig. Laryngoscope 123 (12), 3172–3177.
Hitchcock, Y.J., Tward, J.D., Szabo, A., Bentz, B.G., Shrieve, D.C., 2009. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 73 (3), 779–788.
Kaltenbach, J.A., Church, M.W., Blakley, B.W., McCaslin, D.L., Burgio, D.L., 1997. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol. Head Neck Surg. 117 (5), 493–500.
Knight, K.R., Kraemer, D.F., Neuwelt, E.A., 2005. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 23, 8588–8596.
Kondo, H., Fukuda, H., Ono, H., et al., 2001. Sodium thiosulfate solution spray for relief of irritation caused by Lugol's stain in chromoendoscopy. Gastrointest. Endosc. 53 (2), 199–202.
Kushner, B.H., Budnick, A., Kramer, K., Modak, S., Cheung, N.K., 2006. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107, 417–422.
Laurell, G., Andersson, A., Engstrom, B., Ehrsson, H., 1995. Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the Guinea pig. Canc. Chemother. Pharmacol. 36 (1), 83–86.
Leitao, D.J., Blakley, B.W., 2003. Quantification of sodium thiosulphate protection on cisplatin-induced toxicities. J. Otolaryngol. 32 (3), 146–150.
Li, Y., Womer, R.B., Silber, J.H., 2004. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Canc. 40 (16), 2445–2451.
Liang, F., Schulte, B.A., Qu, C., Hu, W., Shen, Z., 2005. Inhibition of the calcium- and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 135 (1), 263–271.
Liu, H.J., Dong, M.M., Chi, F.L., 2006. Dexamethasone pharmacokinetics in Guinea pig inner ear perilymph. ORL J Otorhinolaryngol. Relat Spec 68 (2), 93–98.
Marckmann, P., Nielsen, A.H., Sloth, J.J., 2008. Possibly enhanced gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis. Nephrol. Dial. Transplant. 23 (10), 3280–3282.
Montaguti, M., Brandolini, C., Ferri, G.G., Hatzopoulos, S., Prete, A., Pession, A., 2002. Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol. Ital. 22 (1), 14–18.
Moroso, M.J., Blair, R.L., 1983. A review of cis-platinum ototoxicity. J. Otolaryngol. 12 (6), 365–369.
Muldoon, L.L., Pagel, M.A., Kroll, R.A., et al., 2000. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin. Canc. Res. 6 (1), 309–315.
Neuwelt, E.A., Brummett, R.E., Doolittle, N.D., et al., 1998. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J. Pharmacol. Exp. Therapeut. 286 (1), 77–84.
Ossorio-Garcia, L., Jimenez-Gallo, D., Arjona-Aguilera, C., Linares-Barrios, M., 2016. Intralesional sodium thiosulfate to treat calciphylaxis. Actas Dermosifiliogr 107 (4), 359–362.
Park, Y.H., Park, C.H., Kim, H.J., 2010. The effect of topical sodium thiosulfate in experimentally induced myringosclerosis. Laryngoscope 120 (7), 1405–1410.
Parnes, L.S., Sun, A.H., Freeman, D.J., 1999. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 109 (7 Pt 2), 1–17.
Pierre, P.V., Engmer, C., Wallin, I., Laurell, G., Ehrsson, H., 2009. High concentrations of thiosulfate in scala tympani perilymph after systemic administration in the Guinea pig. Acta Otolaryngol. 129 (2), 132–137.
Plontke, S.K., Biegner, T., Kammerer, B., Delabar, U., Salt, A.N., 2008. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol. Neurotol. 29 (3), 401–406.
Rybak, L.P., 2007. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg. 15 (5), 364–369.
Saito, T., Zhang, Z.J., Manabe, Y., Ohtsubo, T., Saito, H., 1997. The effect of sodium thiosulfate on ototoxicity and pharmacokinetics after cisplatin treatment in Guinea pigs. Eur. Arch. Oto-Rhino-Laryngol. 254 (6), 281–286.
Salt, A.N., Kellner, C., Hale, S., 2003. Contamination of perilymph sampled from the basal cochlear turn with cerebrospinal fluid. Hear. Res. 182 (1–2), 24–33.
Schaefer, S.D., Post, J.D., Close, L.G., Wright, C.G., 1985. Ototoxicity of low- and moderate-dose cisplatin. Cancer 56 (8), 1934–1939.
So, H., Kim, H., Kim, Y., et al., 2008. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1. J Assoc Res Otolaryngol 9 (3), 290–306.
Stocks, R.M., Gould, H.J., Bush, A.J., 2004. Ototoxic protection of sodium thiosulfate: daily vs constant infusion. Otolaryngol. Head Neck Surg. 40 (11), 115–119.
Togawa, T., Ogawa, M., Nawata, M., Ogasawara, Y., Kawanabe, K., Tanabe, S., 1992. High performance liquid chromatographic determination of bound sulfide and sulfite and thiosulfate at their low levels in human serum by pre-column fluorescence derivatization with monobromobimane. Chem. Pharm. Bull. (Tokyo) 131 (1), 3000–3004.
Wang, J., Lloyd Faulconbridge, R.V., Fetoni, A., Guitton, M.J., Pujol, R., Puel, J.L., 2003. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss

in the Guinea pig. Neuropharmacology 45 (3), 380–393.
Wang, X., Fernandez, R., Dellamary, L., et al., 2011. Pharmacokinetics of dexamethasone solution following intratympanic injection in Guinea pig and sheep. Audiol. Neuro. Otol. 16 (4), 233–241.
Wimmer, C., Mees, K., Stumpf, P., Welsch, U., Reichel, O., Suckfull, M., 2004. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol. Neurotol. 25 (1), 33–40.
Yee, M.S., Blakley, B.W., Begleiter, A., Leith, M., 2008. Delayed sodium thiosulphate administration reduces cisplatin efficacy on mouse EMT6 tumour cells in vitro. J Otolaryngol Head Neck Surg 37 (5), 638–641.
Yerram, P., Saab, G., Karuparthi, P.R., Hayden, M.R., Khanna, R., 2007. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure–role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin. J. Am. Soc. Nephrol. 2 (2), 258–263.
Yu, Z., Gu, L., Pang, H., Fang, Y., Yan, H., Fang, W., 2015. Sodium thiosulfate: an emerging treatment for calciphylaxis in dialysis patients. Case Rep Nephrol Dial 5 (1), 77–82.
Zuur, C.L., Simis, Y.J., Lansdaal, P.E., et al., 2007. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J. Clin. Oncol. 25 (24), 3759–3765.